Cancer Research U.K. launches tumor screening study

Cancer Research U.K. began enrolling patients in the first phase of its Stratified Medicine Program, which is seeking to find cancer biomarkers and establish a genetic testing service in the U.K. The first phase will screen tumor samples from up to 9,000 patients with melanoma, breast, bowel, lung, prostate or ovarian cancer. The first phase is funded by a L5.5 million ($8.6 million) contribution from the non-profit and its industry partners, AstraZeneca plc (LSE:AZN; NYSE:AZN) and Pfizer Inc. (NYSE:PFE). The genetic data and clinical information will be stored in a national database available to researchers. The first phase is slated to complete in 2013. ...